News
Author: admin als-handoff
-
Achieve Reports Financial Results for Second Quarter 2022 and Provides Corporate Update
Company to host conference call at 4:30 PM EDT today, August 11, 2022. SEATTLE, Wash and VANCOUVER, British Columbia, August 11, 2022 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced second quarter 2022 financial…
-
Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 11, 2022
SEATTLE, Wash and VANCOUVER, British Columbia, July 28, 2022 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will report its second quarter financial results and provide an update on the cytisinicline development program…
-
Achieve Life Sciences Announces Granting of New Hire Inducement Awards
SEATTLE, Wash. and VANCOUVER, British Columbia, July 1, 2022 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the Company has issued inducement grants of stock options to two new employees. Achieve’s Board of Directors…
-
Achieve Life Sciences Announces Initiation of Phase 2 ORCA-V1 Clinical Trial Evaluating Cytisinicline for Nicotine e-cigarette Cessation
SEATTLE and VANCOUVER, British Columbia, June 29, 2022 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it has initiated screening of subjects for the ORCA-V1 Phase 2 clinical trial. ORCA-V1 will evaluate the…
-
Achieve Life Sciences Announces Participation at H.C. Wainwright 1st Annual Mental Health Conference
SEATTLE and VANCOUVER, British Columbia, June 21, 2022 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will be participating at the H.C. Wainwright 1st Annual Mental Health Conference. The Conference is…